| Primary information |
|---|
| OV_ID | OV_713 |
| Virus Name | Reovirus |
| Strain | RT3D (Reolysin) |
| Virus type | RNA |
| Virus family | Reoviridae |
| Modification in virus genome | None |
| Virus alone | Yes |
| Virus in combination iwth drug/radiation | No |
| Immune gene induction in virus genome | No |
| Source of cell line | ATCC |
| Origin of cell line | NA |
| Cell line | NA |
| Concentration of cell line | 0 |
| In-vitro toxicity | NA |
| Assay | NA |
| In-vitro virus concentration | NA |
| In-vitro result | NA |
| Model organism | C57Bl/6j mice subcutaneously injected with 5 × 10ⵠB16F10 cells (vaccinated with cell-based Reovirus vaccine 8–12 weeks prior to day 0) |
| In-vivo virus concentration | 1 × 10ⷠPFU to 1 × 10⹠PFU for three weeks |
| In-vivo toxicity | NA |
| In-vivo result | 100% survived till 150 days (Reduction in tumor volume to 0.0 cubic centimeter compared to control 1.4 cubic centimeter after 16 days) |
| Mode of delivery | intravenously |
| Pathway induction | NA |
| Immunogenic effect | Up-regulation of IL-12, IL-5, IL-10, TNF-alpha |
| Clinical trial | NA |
| PMID | 27412241 |